Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,931
datasets available to search
ShareScore release 0.9.0
Dataset results
6,931 results for “Obesity.”
data set regarding to project – Sarcopenia, obesity, sarcopenic obesity and risk of PNS in Polish older people
<p><strong>This data set corresponds with the article titled: Sarcopenia, obesity, sarcopenic obesity and risk of poor nutritional status in Polish community-dwelling older people aged 60 years and over.</strong></p>
Brain-Derived Neurotrophic Factor and extracellular vesicle-derived miRNAs in an Italian cohort of individuals with obesity: a key to explain the link between depression and atherothrombosis.
<p>This record contains raw data related to the article “Brain-Derived Neurotrophic Factor and Extracellular Vesicle-Derived miRNAs in an Italian Cohort of Individuals With Obesity: A Key to Explain the Link Between Depression and Atherothrombosis” </p> <p><em><strong>Abstract: </strong></em></p> <p><strong>Background</strong>: Obesity and depression are intertwined diseases often associated with an increased risk of cardiovascular (CV) complications. Brain-Derived Neurotrophic Factor (BDNF), altered in the brain both of subjects with depression and obesity, provides a potential link between depression and thrombosis. Since the relationship among peripheral BDNF, depression and obesity is not well-defined, the aim of the present report has been to address this issue taking advantage of the contribution played by extracellular vesicle (EV)-derived miRNAs. <strong>Research Process</strong>: Associations among circulating BDNF, depression and EVderived miRNAs related to atherothrombosis have been evaluated in a large Italian cohort of obese individuals (n = 743), characterized by the Beck Depression Inventory (BDI-II) score.<br> <strong>Results</strong>: BDI-II was negatively associated with BDNF levels without a significant impact of the rs6265 BDNF polymorphism; this association was modified by raised levels of IFN-g. BDNF levels were linked to an increase of 80 EV-derived miRNAs and a decrease of 59 miRNAs related to atherosclerosis and thrombosis. Network analysis identified at least 18 genes targeted by these miRNAs, 7 of which involved in depression and CV<br> risk. The observation of a possible link among BDNF, depression, and miRNAs related to atherothrombosis and depression in obesity is novel and may lead to a wider use of BDNF as a CV risk biomarker in this specific subject group.</p>
Obesity and acute stress modulate appetite and neural responses in food word reactivity task
<p>Data used in "Carnell S, Benson L, Papantoni A, Chen L, Huo Y, Wang Z, Peterson BS, Geliebter A. Obesity and acute stress modulate appetite and neural responses in food word reactivity task. PloS one"</p>
Weight stability in adults with obesity initiating medical marijuana treatment
<p>Few studies have evaluated weight change in patients who initiate medical marijuana treatment to address diagnosed health concerns. The objective of this study was to examine whether patients initiating medical marijuana use for a qualifying health condition experienced changes in health and biopsychosocial functioning over time, including weight gain or loss. Specifically, this observational, longitudinal study evaluated changes in the Body Mass Index (BMI) of adults with co-morbid obesity (Body Mass Index [BMI] ≥ 30 kg/m2) and severe obesity (BMI ≥ 40 kg/m2) who were starting medical marijuana treatment for any of the 23 qualifying medical conditions at one of three dispensaries in Pennsylvania. Height and weight measurements were collected at baseline (prior to medical marijuana use) and then 90 days (± 14 days) later. Participants included in analyses (n = 52, M = 55.0 ± 13.6 years, 59.6% female) had a mean baseline BMI of 36.2 ± 5.4 kg/m2 and the majority sought medical marijuana for chronic pain (73.1%). No significant change in BMI was observed from baseline to month three (p > 0.05) in the sample. Additionally, no significant change in BMI was observed in the subset of patients with severe obesity (n = 12, p > 0.05). Our findings are limited by low follow-up rates and convenience sampling methodology but may help to mitigate weight gain concerns in the context of medical marijuana use.</p>
Multi-omic brain and behavioral correlates of cell-free fetal DNA methylation in macaque maternal obesity models (NMR datasets, maternal plasma and infant brain)
<p>Maternal obesity during pregnancy is associated with neurodevelopmental disorder (NDD) risk. We utilized integrative multi-omics to examine maternal obesity effects on offspring neurodevelopment in rhesus macaques by comparison to lean controls and two interventions. Differentially methylated regions (DMRs) from longitudinal maternal blood-derived cell-free fetal DNA (cffDNA) significantly overlapped with DMRs from infant brain. The DMRs were enriched for neurodevelopmental functions, methylation-sensitive developmental transcription factor motifs, and human NDD DMRs identified from brain and placenta. Brain and cffDNA methylation levels from a large region overlapping mir-663 correlated with maternal obesity, metabolic and immune markers, and infant behavior. A DUX4 hippocampal co-methylation network correlated with maternal obesity, infant behavior, infant hippocampal lipidomic and metabolomic profiles, and maternal blood measurements of DUX4 cffDNA methylation, cytokines, and metabolites. Ultimately, maternal obesity altered infant brain and behavior, and these differences were detectable in pregnancy through integrative analyses of cffDNA methylation with immune and metabolic factors. </p>
Impact of maternal obesity on the gestational metabolome and infant metabolome, brain, and behavioral development in rhesus macaques
<p>Maternal gestational obesity is associated with elevated risks for neurodevelopmental disorder, including autism spectrum disorder. However, the mechanisms by which maternal adiposity influences fetal developmental programming remain to be elucidated. We aimed to understand the impact of maternal obesity on the metabolism of both pregnant mothers and their offspring, as well as on metabolic, brain, and behavioral development of offspring by utilizing metabolomics, protein, and behavioral assays in a non-human primate model. We found that maternal obesity was associated with elevated inflammation and significant alterations in metabolites of energy metabolism and one-carbon metabolism in maternal plasma and urine, as well as in placenta. Infants born to obese mothers were significantly larger at birth compared to those born to lean mothers. Additionally, they exhibited significantly reduced novelty preference and significant alterations in their emotional response to stress situations. These changes coincided with differences in phosphorylation of enzymes in the brain mTOR signaling pathway between infants born to obese and lean mothers and correlated with the concentration of maternal plasma betaine during pregnancy. In summary, gestational obesity significantly impacted the infant systemic and brain metabolome and adaptive behaviors.</p>
Diet-induced obesity and NASH impair disease recovery in SARS-CoV-2-infected golden hamsters
<p>Obese patients with nonalcoholic steatohepatitis (NASH) are prone to severe forms of COVID-19. There is an urgent need for new treatments that lower the severity of COVID-19 in this vulnerable population. To better replicate the human context, we set up a diet-induced model of obesity associated with dyslipidemia and NASH in the golden hamster (known to be a relevant preclinical model of COVID-19). A 20-week, free-choice diet induces obesity, dyslipidemia and NASH (liver inflammation and fibrosis) in golden hamsters. Obese NASH hamsters have higher blood and pulmonary levels of inflammatory cytokines. In the early stages of a SARS-CoV-2 infection, the lung viral load and inflammation levels were similar in lean hamsters and obese NASH hamsters. However, obese NASH hamsters showed worse recovery (i.e. less resolution of lung inflammation 10 days post-infection (dpi), and lower body weight recovery on dpi 25). Obese NASH hamsters also exhibited higher levels of pulmonary fibrosis on dpi 25. Unlike lean animals, obese NASH hamsters infected with SARS-CoV-2 presented long-lasting dyslipidemia and systemic inflammation. Relative to lean controls, obese NASH hamsters had lower serum levels of angiotensin-converting enzyme 2 activity and higher serum levels of angiotensin II - a component known to favor inflammation and fibrosis. Even though the SARS-CoV-2 infection resulted in early weight loss and incomplete body weight recovery, obese NASH hamsters showed sustained liver steatosis, inflammation, hepatocyte ballooning, and marked liver fibrosis on dpi 25.<strong> </strong>We conclude that diet-induced obesity and NASH impair disease recovery in SARS-CoV-2-infected hamsters. This model might be of value in characterizing the pathophysiologic mechanisms of COVID-19 and in evaluating the efficacy of treatments for the severe forms of COVID-19 observed in obese patients with NASH.</p>
NanoString GeoMx DSP dataset from 50 ROIs under maternal obesity and chow diet treatments.
<p>NanoString GeoMx Digital Spatial Profiler data from 49 ROIs under maternal obesity conditions. Details of each ROIs are included in Annotation files.</p>
Nutrition UP 65 study: The association between 25(OH)D levels, frailty status and obesity indices in older adults database
<p>This study database derives from Nutrition UP 65 study main database. The association between 25(OH)D levels, frailty status and obesity indices in older adults was evaluated. This database was prepared according to the recommendations of the following article: "Hrynaszkiewicz Iain, Norton Melissa L, VickersAndrew J, Altman Douglas G. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers BMJ 2010; 340:c181".</p>
Yogurt supplementation attenuates insulin resistance in obese mice by reducing metabolic endotoxemia and inflammation
<p><strong>Background</strong></p> <p>Inflammation is an underlying mechanism for development of obesity-related health complications. Yogurt consumption inhibits obesity-associated inflammation, but the tissue-specific mechanisms have not been adequately described.</p> <p><strong>Objectives</strong></p> <p>We aimed to determine the tissue-specific responses by which yogurt supplementation inhibits inflammation.</p> <p><strong>Methods</strong></p> <p>C57BL/6 male mice (5 weeks old) were fed a Teklad Global 14% Protein Rodent Maintenance diet as a control or a high-fat diet (60% calories from fat) to induce obesity for 11 weeks, followed by feeding a Western diet (WD; 43% carbohydrate & 42% fat) or WD supplemented with 5.6 % lyophilized yogurt powder for 3 weeks to test for the impact of yogurt supplementation. Markers of metabolic endotoxemia and inflammation were assessed in plasma and tissues. Cecal and fecal microbiota were profiled by 16S rRNA sequencing.</p> <p><strong>Results</strong></p> <p>In obese mice, relative to the WD control group, yogurt supplementation attenuated HOMA-IR by 57%) (p=0.020), plasma TNF-a by 31% (p<0.05) and colonic IFN-g by 46% (p=0.0034), which were accompanied by a 40% reduction in plasma LBP (p=0.0019) and 45% less colonic <em>Lbp</em> expression (p=0.037), as well as alteration in the beta diversity of cecal microbiota (p=0.0090) and relative abundance of certain cecal microbes (e.g., <em>Lachnospiraceae Dorea longicatena</em> with p=0.049). There were no differences in the LBP, <em>Lbp</em>, and <em>Cd14</em> levels in the liver and small intestine between obese mice with and without yogurt supplementation (p>0.05).</p> <p><strong>Conclusions</strong></p> <p>Yogurt consumption inhibited obesity-induced inflammation in mice by modulating colonic endotoxin detoxification, changing the gut microbiota, and improving glucose metabolism. This work helps to establish the underlying mechanisms by which yogurt consumption affects markers of metabolic and immune health.</p>
Calorie restriction and pravastatin administration during pregnancy in obese rhesus macaques modulates maternal and infant metabolism and infant brain and behavioral development
<p>Maternal obesity has been associated with a higher risk of pregnancy-related complications in mothers and offspring; however, effective interventions have not yet been developed. We tested two common interventions, calorie restriction and pravastatin administration, during pregnancy in a rhesus macaque model with the hypothesis that these interventions would normalize metabolic dysregulation in pregnant mothers leading to an improvement in infant metabolic and cognitive/social development. A total of 19 obese mothers were assigned to either one of the two intervention groups (n=5 for calorie restriction; n=7 for pravastatin) or an obese control group (n=7) with no intervention, and maternal gestational samples and postnatal infant samples were compared with lean control mothers (n=6). Gestational calorie restriction normalized one-carbon metabolism dysregulation in obese mothers but altered energy metabolism in their offspring. Although administration of pravastatin during pregnancy tended to normalize blood cholesterol in the mothers, it potentially impacted the gut microbiome and kidney function of their offspring. In the offspring, both calorie restriction and pravastatin administration during pregnancy tended to normalize the activity of AMPK in the brain at 6 months, and while results of the Visual Paired-Comparison test, which measures infant recognition memory, were not significantly impacted by either of the interventions, gestational pravastatin administration, but not calorie restriction, tended to normalize anxiety assessed by the Human Intruder test. Although the two interventions tested in a non-human primate model led to some improvements in metabolism and/or infant brain development, negative impacts were also found in both mothers and infants. Our study emphasizes the importance of assessing gestational interventions for maternal obesity on both maternal and offspring long-term outcomes.</p>
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
<p>Importance: Obesity and metabolic disorders have been associated with an increased risk of cancer and with poorer outcomes in many cohorts of breast cancer (BC) patients, with poor evidence from Mediterranean cohorts. <br> Objective: To investigate the prognostic potential of anthropometric variables, namely body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), as well as Metabolic Syndrome (MetS) and its components, in early BC patients living in a Southern Mediterranean region of Italy.<br> Design: Prospective cohort study enrolling consecutive early BC patients who were treated between January 2009 and December 2013 in Southern Italy. Median follow-up was 11.8 years and ended on June 15th 2022. Physicians who measured the study variables were blinded to patient groupings.<br> Setting: Multicenter study enrolling consecutive, early BC patients referred to specialized cancer centers.<br> Participants: A total of 955 early BC patients consecutively treated at the Istituto Nazionale dei Tumori, “G. Pascale” and at the Policlinico University Hospital “Federico II”, Naples, Italy, were enrolled. All study subjects provided written informed consent to participate. <br> Intervention(s) (for clinical trials) and exposure (for observational studies): Anthropometric measurements and indices (BMI, hip circumference and WC) were collected. MetS was defined according to NCEP-ATP III criteria. MetS components were categorized as 0, 1-2 or ≥3. <br> Main Outcomes and Measures: Overall survival and BC-specific survival. <br> Results: Mean age was 55.3 years (±12.5 years); 61% of patients were post-menopausal. At the end of follow-up, 208 (22%) patients had died, 131 (14%) of whom from BC. Obesity (BMI≥30 kg/m2) was found in 29% of enrolled patients (14% in pre- and 38% in post-menopause); 24% of patients met the criteria for a diagnosis of MetS (7% in pre- and 36% in post-menopause), whereas 1-2 MetS criteria were found in 53% of patients<br> High WC or WHR were associated with a moderately increased risk of all-cause mortality (WC ≥ 88 cm, HR=1.39, 95%CI: 1.00-1.94; WHR > 0.85, HR=1.62, 95%CI: 1.12-2.37). Furthermore, an increased risk of all-cause mortality was observed with the presence of MetS (HR=1.61, 95%CI: 1.12-2.32). An increased BC-specific mortality risk was found in obese patients (BMI≥30 kg/m2, HR=1.72, 95%CI: 1.06-2.78) and in those with WC ≥88 (HR=1.71, 95%CI: 1.12-2.61). High WHR was also associated with increased risk of BC-specific mortality, both when evaluated as a categorical variable (WHR>0.85, HR=1.80, 95%CI: 1.13-2.86) and as a continuous variable (for each 0.1-U increase in WHR, HR=1.33, 95%CI: 1.08-1.63). The presence of MetS was associated with an 81% increased risk of BC-specific mortality (HR=1.81, 95%CI: 1.51-2.85). <br> These associations varied according to menopausal status. In particular, in pre-menopausal patients higher BMI was associated with an increased risk of both all-cause and BC-specific mortality (HR=1.43 and HR=1.58, respectively). In post-menopausal women an increased risk of all-cause mortality was found only in the presence of ≥3 MetS components (HR=2.77, 95%CI: 1.09-7.06). The associations among anthropometric variables and all-cause and BC-specific mortality also varied according to BC subtype. Triple negative BC was the only disease subtype that wasn’t independently associated with BMI, WC, WHR or MetS or all-cause and BC-specific mortality.<br> Conclusions and Relevance: Central obesity and metabolic disorders result in a highly increased risk of BC death. The magnitude of this effect suggests that obesity may nullify the benefit of effective BC therapies. Active lifestyle interventions to maintain optimal body weight and to prevent MetS should be recommended for several expected beneficial effects, including a potential reduction in BC-specific mortality.</p>
Data from: Investigating the human and non-obese diabetic mouse MHC class II immunopeptidome using protein language modelling.
<p><strong>Background</strong>: Identifying peptides associated with the major histocompability complex class II (MHCII) is a central task in the evaluation of the immunoregulatory function of therapeutics and drug prototypes. MHCII-peptide presentation prediction has multiple biopharmaceutical applications, including the safety assessment of biologics and engineered derivatives in silico, or the fast progression of antigen-specific immunomodulatory drug discovery programs in immune disease and cancer. This has resulted in the collection of large–scale data sets on adaptive immune receptor antigenic responses and MHC-associated peptide proteomics. In parallel, recent deep learning algorithmic advances in natural language processing (NLP) and protein language modelling (PLM) have shown potential in leveraging large collections of sequence data and improve MHC presentation prediction. <strong>Methodology</strong>: We trained a compact transformer model (AEGIS) on human and mouse MHCII immunopeptidome data, including a preclinical murine model, and evaluated its performance on the peptide presentation prediction task. <strong>Data</strong>: The data and models used in AEGIS are contained in the uploaded tar files. <strong>Results</strong>: The transformer performs on par with existing deep learning algorithms and that combining datasets from multiple organisms increases model performance (see preprint). We trained variants of the model with and without MHCII information. In both alternatives, the inclusion of peptides presented by the I-Ag7 MHC class II molecule expressed by the non-obese diabetic (NOD) mice enabled the in silico prediction of presented peptides in a preclinical type 1 diabetes model organism, which has promising therapeutic applications.</p>
The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity
ClinicalTrials.gov study NCT01327976. IPD Sharing: NO. Countries: 2. Publications: 2.
The Effect of White Tea Consumption on Obesity
ClinicalTrials.gov study NCT06357273. IPD Sharing: NO. Countries: 1. Publications: 4.
The Effects of Treating Obese and Lean Patients With Sleep Apnea
ClinicalTrials.gov study NCT01578031. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
ClinicalTrials.gov study NCT00673387. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Reduced Carbohydrate Versus Fat in Obese Subjects
ClinicalTrials.gov study NCT00846040. IPD Sharing: Not stated. Countries: 1. Publications: 8.
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
ClinicalTrials.gov study NCT04184622. IPD Sharing: YES. Countries: 10. Publications: 13.
Computer-Delivered Intervention for Individuals With Obesity and Elevated Anxiety Sensitivity
ClinicalTrials.gov study NCT03917901. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.